The last few decades have witnessed remarkable achievements in the development of immunosuppressive drugs, made possible by significant advances in molecular immunology and improved understanding of the mechanisms by which cells communicate. The identification of the relevant cells involved in a pathological process is the key to understanding effective immunosuppressive strategies. For example, understanding the role of the activated CD4 + T cell in cellular rejection of grafts has revolutionised transplant therapies.
Many immunosuppressive drugs are used for unlicensed indications. It is difficult to achieve a balance between adequate control of the disease process and overimmunosuppression leading to infections and malignancy. This review examines the commoner agents in use, highlighting which part of the immune system they modify, their most important side effects and monitoring strategies (Tables 1-3 ).
The adaptive immune system of both T and B cells relies on the non-specific uptake of antigen by antigen presenting cells (APCs) (eg monocytes and dendritic cells). Specific inhibitors of this process are not commercially available. Drugs such as minocycline 4 and chloroquine 4, 5 can inhibit the processing of antigens by APCs, which is the reason for their anti-inflammatory effect. Methotrexate is a folic acid antagonist, given once weekly, which inhibits the enzyme dihydrofolate reductase. Its main effect is inhibition of DNA synthesis but it also interferes with RNA and protein synthesis and causes clonal deletion of activated T cells. 8 Methotrexate suppresses inflammatory responses through release of adenosine; this induces apoptosis of activated lymphocytes and inhibits the synthesis of purines and pyrimidines. Methotrexate is well absorbed orally, but subcutaneous, intramuscular or intravenous bioavailability is higher.
Specific immunosuppressive drugs
The advent of HIV and AIDS forcibly demonstrated the importance of the T helper cell in controlling the immune response. T cells recognise antigen presented to them by APCs using the T cell receptor (TCR). Following TCR engagement, a complex cascade of signals results in activation and proliferation of the T cell. This process is critically dependent upon the concentration of intracellular calcium.
Calcineurin inhibitors
The calcium-dependent phosphatase calcineurin is critical for diverse T cell signalling activities such as interleukin (IL)-2 production, apoptosis, cytoskeletal deployment and control of ion channels. Calcineurin inhibitors cause apoptosis of activated T cells as well as inhibiting the production of the key T cell cytokine IL-2.
Calcineurin inhibitors such as ciclosporin (CSA) and tacrolimus revolutionised transplantation surgery but are associated with significant dose-limiting side effects. Blood calcineurin inhibitor concentrations correlate with toxicity but do not directly translate into degree of immunosuppression. T cell counts and T cell proliferation assays do not correlate with immunosuppression either, although tests such as ImmuKnow 9 are being assessed and may be commercially available in the near future.
Several forms of CSA are available including microemulsions and capsules. CSA has a narrow therapeutic window, with wide inter-and intrapatient pharmacokinetics. It is essential always to prescribe CSA by brand name as there are wide differences in bioavailability between products. 10 Cyclophosphamide Drug levels not routinely available FBC, U&Es, urinalysis every 2-4 weeks *Drug levels may be monitored using a variety of approaches; local laboratories should be consulted regarding the timing of samples in relation to the dose and acceptable blood levels. **Brackets denote common abnormalities. creat = creatinine; CSA = ciclosporin; FBC = full blood count; iv = intravenous; LFT = liver function test; TPMT = thiopurine methyltransferase; U&E = urea and electrolyte. 11 A subset of T cells, CD4 + CD25 + regulatory T cells (T REG ), play an important role in allograft tolerance; their functional activity depends on signalling via the IL-2 receptor. Rapamycin promotes apoptosis of alloreactive T cells and strongly preserves T REG , in contrast to CSA, which may favour the use of rapamycin in the induction of tolerance. 12 
Mammalian target of rapamycin
T cell function is also controlled by another enzyme, mammalian target of rapamycin (mTOR), which is essential for regulating intracellular signalling through the IL-2 receptor. Inhibition of mTOR results in arrest of cell-
De novo nucleotide synthesis inhibitors
AZA is enzymatically converted and incorporated into DNA, inhibiting purine biosynthesis and proliferation of T and B lymphocytes. The major side effect of AZA is therefore myelosuppression, including leukopenia, anaemia and thrombocytopenia. These side effects are generally dose-dependent and resolve in 7-10 days with dose reduction.
Individuals with a polymorphism of the thiopurine methyl transferase enzyme (TPMT) cannot metabolise AZA effectively, leading to severe side effects. Screening for this is now possible in advance of AZA therapy by measuring TPMT activity (phenotype) or genotype. Patients with intermediate TPMT activity or who are heterozygotes need a 50% reduction in the standard dose; those with homozygous TPMT deficiency should not receive AZA or only extremely low doses. 13, 14 Mycophenolic acid inhibits inositol monophosphate dehydrogenase, preventing de novo purine biosynthesis in a similar way to AZA. Its function is unique in that it blocks IL-2-mediated proliferation but does not inhibit cell survival and Fas-mediated apoptosis of activated T lymphocytes. 15 Mycophenolic acidbased drugs include mycophenolate mofetil (MMF) and a newer agent, mycophenolate sodium, an entericcoated prodrug of mycophenolic acid associated with fewer gastrointestinal side effects than MMF. 16 Dihydroorotate dehydrogenase (DHOD) is a key enzyme in de novo pyrimidine synthesis. Leflunomide, FK778 (a leflunomide derivative), brequinar sodium and atovaquone are chemically distinct but all block DHOD activity. 17 Leflunomide is used as an immunomodulatory agent and is licensed as a disease-modifying antirheumatic drug in rheumatoid arthritis. 18 The malononitrilamide FK778 is a new class of low molecular weight immunosuppressants that block both T cell and humoral immune responses. 19 
Newer immunomodulatory agents
Thalidomide and its analogues, lenalidomide and CC-4047 (Actimid) provide immunomodulation through inhibition of tumour necrosis factor-α production in monocytes and costimulatory effects on human CD8 + T cells. 20 Mizoribine, like mycophenolate, inhibits inosine monophosphate dehydrogenase; long-term use seems to prevent renal relapses and reduce prednisolone requirement among severe proliferative lupus nephritis patients. A few anecdotal reports show mizoribine is effective in steroid-resistant nephrotic syndrome. 21 15-Deoxyspergualin has properties similar to CSA and tacrolimus. It inhibits the activation of APCs and monocytes without affecting IL-2 synthesis. 22 FTY 720 is a synthetic molecule structurally related to myriocin, a fungal metabolite. FTY 720 reduces the number of circulating lymphocytes, especially T helper cells, by downregulation of sphingosine receptors and redirecting them to the lymph nodes. FTY 720 has shown considerable promise in prolonging renal allograft transplant survival 23 and is undergoing trials in pancreatic islet cell transplantation for type 1 diabetes.
Practicalities of immunosuppression
Treatment with immunosuppressive therapies requires an understanding of the speed of onset of the drugs and effective monitoring systems (Table 2) is considerably slower. Effective blood levels of calcineurin inhibitors are reached in days, but sustained effects may be seen only after several weeks, whereas AZA may take two or three months to peak effect. As non-steroid agents begin to take effect, the steroid dose can gradually be tapered. A good general principle is that powerful combinations of immunosuppressants (eg methyl prednisolone with cyclophosphamide) are used initially, with milder agents (eg AZA or methotrexate) replacing them once disease control is established. However, this approach may not be required in all clinical settings. Disease-specific, evidencebased guidelines should be consulted frequently as new studies emerge.
The future
Oral immunosuppressive drugs are widely used for both licensed and unlicensed indications. All physicians need to be aware of the possible uses, interactions and side effects of these drugs as patients may present acutely with infectious, malignant or other complications related to their immunosuppression.
